{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T22:56:21Z","timestamp":1785538581316,"version":"3.56.0"},"reference-count":45,"publisher":"Wiley","issue":"S60","license":[{"start":{"date-parts":[[2009,4,24]],"date-time":"2009-04-24T00:00:00Z","timestamp":1240531200000},"content-version":"vor","delay-in-days":4527,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[1996,12]]},"abstract":"<jats:p><jats:bold>Abstract:\u2002<\/jats:bold>From the studies that have been done by many laboratories over the last 2 decades, it is now clear that the toxicities produced by many drugs are due to their reactive metabolites. It is thought that, in many cases, reactive metabolites cause toxicity by binding covalently to tissue proteins. However, until recently it was difficult to identify these protein targets. Due to the development of an immunochemical approach, this problem has been overcome, as is illustrated here by studies that have been conducted on the metabolic basis of the idiosyncratic hepatitis caused by the inhalation anaesthetic halothane. The major problem to solve in the future will be to determine how protein adduct formation leads to toxicity. It is possible that protein adduct formation may alter an important cellular function or may lead to immunopathology, as is thought to occur in the case of halothane hepatitis. If an allergic reaction is suspected, purified protein targets of reactive metabolites can serve as antigens for identifying sensitized individuals. This information can be used to prevent not only an allergic reaction to the drug, but possibly cross\u2010reactions to other drugs that are structurally related. Another important application of these studies is the design of safer alternative drugs that will not produce structurally similar toxic reactive metabolites.<\/jats:p>","DOI":"10.1111\/j.1600-0609.1996.tb01654.x","type":"journal-article","created":{"date-parts":[[2010,7,18]],"date-time":"2010-07-18T08:45:24Z","timestamp":1279442724000},"page":"98-104","source":"Crossref","is-referenced-by-count":23,"title":["Mechanisms, chemical structures and drug metabolism"],"prefix":"10.1111","volume":"57","author":[{"given":"L.R.","family":"Pohl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.R.","family":"Pumford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.L.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2009,4,24]]},"reference":[{"key":"e_1_2_1_2_2","first-page":"91","volume-title":"Anonymous hepatotoxicity: the adverse effects of drugs and other chemicals on the liver","author":"Zimmerman HJ","year":"1978"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.pa.30.040190.001125"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.pa.32.040192.002351"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.3109\/03602539308993981"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.pa.30.040190.003131"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(19)39733-9"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1021\/tx00018a001"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1006\/taap.1994.1195"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/0167-5699(95)80133-2"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.pa.28.040188.002055"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(87)90706-4"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.3109\/03602539008991445"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2008-1040486"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-69088-4_3"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(88)80342-5"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI113603"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/0091-6749(88)90062-0"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1021\/tx00036a006"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1042\/bst0190191"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000542-199511000-00030"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840080627"},{"key":"e_1_2_1_23_2","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/S0022-3565(25)39143-3","article-title":"Identification by immunoblotting of three halothane\u2010induced liver microsomal polypeptide antigens recognized by antibodies in sera from patients with halothane\u2010associated hepatitis","volume":"242","author":"Kenna JG","year":"1987","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_1_24_2","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/S0022-3565(25)24104-0","article-title":"Metabolic basis for a drug hypersensitivity: antibodies in sera from patients with halothane hepatitis recognize liver neoantigens that contain the trifluoroacetyl group derived from halothane","volume":"245","author":"Kenna JG","year":"1988","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_1_25_2","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/S0090-9556(25)08653-2","article-title":"Factors affecting the expression of trifluoroacetylated liver microsomal protein neoantigens in rats treated with halothane","volume":"18","author":"Kenna JG","year":"1990","journal-title":"Drug Metab Dispos"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1021\/tx00038a009"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4684-5134-4_61"},{"key":"e_1_2_1_28_2","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/S0022-3565(25)22885-3","article-title":"Immunological studies on the mechanism of halothane\u2010induced hepatotoxicity: immunohistochemical evidence of trifluoroacetylated hepatocytes","volume":"233","author":"Satoh H","year":"1985","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.3109\/03602538909103537"},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.86.1.322"},{"key":"e_1_2_1_31_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.88.4.1407"},{"key":"e_1_2_1_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(90)94224-L"},{"key":"e_1_2_1_33_2","first-page":"255","article-title":"Patients with halothane hepatitis have serum antibodies directed against glucose\u2010regulated stress protein GRP78\/BiP","volume":"12","author":"Davila JC","year":"1992","journal-title":"Toxicologist"},{"key":"e_1_2_1_34_2","doi-asserted-by":"publisher","DOI":"10.1021\/tx00035a004"},{"key":"e_1_2_1_35_2","doi-asserted-by":"publisher","DOI":"10.1021\/tx00027a014"},{"key":"e_1_2_1_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-291X(91)90161-Y"},{"key":"e_1_2_1_37_2","doi-asserted-by":"publisher","DOI":"10.1006\/abbi.1995.0060"},{"key":"e_1_2_1_38_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840180417"},{"key":"e_1_2_1_39_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4684-5877-0_12"},{"key":"e_1_2_1_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(93)90474-B"},{"key":"e_1_2_1_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(93)92005-E"},{"key":"e_1_2_1_42_2","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1016\/S0022-3565(25)22542-3","article-title":"Sera from patients with halothane hepatitis contain antibodies to halothane\u2010induced liver antigens which are not detectable by immunoblotting","volume":"270","author":"Knight TL","year":"1994","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_1_43_2","doi-asserted-by":"publisher","DOI":"10.1021\/tx00047a014"},{"key":"e_1_2_1_44_2","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0090-9556(25)06888-6","article-title":"Potential metabolic basis for enflurane hepatitis and the apparent cross\u2010sensitization between enflurane and halothane","volume":"16","author":"Christ DD","year":"1988","journal-title":"Drug Metab Disp"},{"key":"e_1_2_1_45_2","doi-asserted-by":"publisher","DOI":"10.1159\/000237113"},{"key":"e_1_2_1_46_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000542-198812000-00006"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1600-0609.1996.tb01654.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1600-0609.1996.tb01654.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,23]],"date-time":"2025-02-23T02:26:58Z","timestamp":1740277618000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1600-0609.1996.tb01654.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1996,12]]},"references-count":45,"journal-issue":{"issue":"S60","published-print":{"date-parts":[[1996,12]]}},"alternative-id":["10.1111\/j.1600-0609.1996.tb01654.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1600-0609.1996.tb01654.x","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[1996,12]]}}}